STOCKS TELEGRAPH

Tag: DARE Stock Price

  • Ovaprene Trial Update Boosts Daré Bioscience Market Performance

    Ovaprene Trial Update Boosts Daré Bioscience Market Performance

    Daré Bioscience, Inc. (NASDAQ: DARE) shares surged by 74.16% to $4.38 as of the last check during morning trading following the release of encouraging interim data from a Phase 3 clinical trial.

    Positive Interim Analysis Supports Efficacy and Safety

    The trial evaluates the contraceptive effectiveness, safety, and acceptability of Ovaprene, DARE’s investigational monthly, hormone-free intravaginal contraceptive. Notably, no FDA-approved products currently exist within this contraceptive category, placing Ovaprene in a potentially groundbreaking position.

    The study’s Data Safety Monitoring Board (DSMB) conducted a planned interim review and recommended that the trial continue without any modifications. The interim analysis revealed that approximately 9% of women using Ovaprene experienced pregnancy—aligned with prior expectations and data from the pre-pivotal postcoital test study. The effectiveness of ovaprene as a hormone-free contraception is well supported by these studies.

    Crucially, during the review, no significant safety issues were brought forward. Vaginal odor was the most frequent product-related adverse event, causing almost 17% of participants to stop the research. Overall tolerability remained acceptable in spite of this, and most women who finished the experiment had a high propensity to use Ovaprene if it were made commercially accessible.

    A New Direction for Women’s Health

    Ovaprene has the potential to address a significant unmet need in the contraceptive market, according to Daré Bioscience, which expressed confidence about these findings. The business sees Ovaprene as a potentially game-changing solution in reproductive health, given the rising desire among American women for hormone-free birth control solutions.

    Commercial Prospects with Bayer and Future Milestones

    Commercial momentum may accelerate if Bayer elects to exercise its exclusive U.S. commercialization rights following trial completion. This decision would involve a $20 million payment to Daré Bioscience.

    In total, Daré Bioscience stands to gain up to $310 million in commercial milestone payments, along with double-digit tiered royalties on net sales. These payments are subject to a minority interest provision under a royalty purchase agreement made in April 2024.

  • Dare Bioscience, Inc. (DARE) Stock Rocketing Higher, Here’s the Reason

    Dare Bioscience, Inc. (DARE), a clinical-stage biopharmaceutical company, has soared 37.61% in aftermarket trading session. Consequently, DARE is trading at $2.92 at the time of the writing. On Tuesday, DARE closed the day at $2.12 after surging 10.52% during regular trading hours. The increase in stock could be attributed to the approval of XACIATO by the FDA.

    Why DARE Rising?

    On Tuesday, DARE announced that the Food and Drug Administration (FDA) has approved XACIATO, clindamycin phosphate vaginal gel, 2%, for treating bacterial vaginosis in girls having age 12 years or older. Bacterial vaginosis is among the most common causes of vaginitis around the globe. It is estimated that vaginitis affects about 21 million women in the US alone. The FDA approval of XACIATO comes three years after the company licensed that technology.

    Q3 2021 Operational Results

    On 10th November, DARE released the operational results for the third quarter of fiscal 2021. The quarter ended on 30th September. The company bore total operating expenses of $12.6 million during the quarter against $7.5 million for the same period of 2020. The net loss suffered by the company during the three-month period stood at $12.66 million against $7.5 million for the same period of 2020. The net loss per basic and diluted share for the quarter stood at $0.18 against $0.24 for the same period of 2020.

    Executive Commentary

    While commenting on the results, Sabrina Martucci Johnson, President, and CEO of DARE said that the company has made continued efforts and significant progress on several of the key clinical and strategic corporative initiatives during the quarter. Based on those, the company is gearing up for eventful next few months and looks forward to providing updates as its progress continues in a forward direction.  

    Future Outlook for DARE

    During the last month, DARE stock has jumped up more than 32%. Based on that, analysts are predicting that dare stock should be on the radar of potential investors, who could reap numerous benefits from the stock in the near future.

  • What Explains The 61% Rise In DARE Stock Premarket?

    What Explains The 61% Rise In DARE Stock Premarket?

    Shares of Daré Bioscience Inc. (DARE) were up 61.18% in pre-market trading as of the last check at $2.45. In yesterday’s session, shares of DARE dropped -3.90% at $1.52. DARE stock fluctuated between $1.46 and $1.60 during the day. There were 3.19 million shares traded, which is above DARE’s daily volume of 2.47 million over the last 50 days and its year-to-date volume of 2.55 million.

    Shares of DARE stock have gained 50.50% in the last 12 months, but have declined -9.52% in the last week. For the past six months, DARE stocks have gained 16.03%, and for the past three months, the stock has declined -11.11%. DARE stock’s returns for this year have been 13.43%.  DARE’s stock rose despite no current news, and we can then identify recent developments for a deeper analysis.

    What happened recently at DARE?

    Daré Bioscience develops innovative products for women’s health as a clinical-stage biopharmaceutical company. As part of its mission, DARE brings to market a wide range of differentiated therapies for women debating contraception, vaginal health, sexual health, and fertility.

    The Phase 1 clinical trial of DARE-HRT1 by Daré Bioscience recently reported positive topline results.

    • DARE-HRT1 is a new IVR technology that delivers bio-identical 17-estradiol and bio-identical progesterone continuously for 28 days as part of a hormone therapy (HT) regimen to treat vasomotor symptoms (VMS) and genitourinary syndrome associated with menopause.
    • Two different active pharmaceutical ingredients were successfully delivered by DARE-HRT1 reliably over 28 days.
    • It is a great achievement for Daré and for the IVR platform to generate positive topline data in its first Phase 1 study utilizing novel IVR technology.
    • The use of hormone therapy for some women can relieve symptoms of menopause such as hot flashes and vaginal dryness while also preventing bone loss.
    • The North American Menopause Society’s guidance on hormone therapy includes that dosing estrogen and progestogen in combination may offer important benefits to women and NAMS observed that non-oral routes of administration may offer advantages over orally administered therapies.

    What DARE study has demonstrated?

    Daré Bioscience (DARE) is encouraged by the Phase 1 results since these data demonstrate DARE-HRT1’s ability to meet its dual release objectives. IVR technology played a big role in DARE-HRT1’s success as it provides hormone therapy as well as platform technology. Compared to current vaginal drug delivery solutions, Dare-HRT1’s IVR technology may offer a more flexible and convenient way to deliver drugs to women as it allows them to release one or more drugs at a desired rate over time and at their convenience as well.